Clinical trial · Observational
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC
NCT06762379CI-TRIAL-00106283L2-267recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer (mPC) | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patient with metastatic prostate cancer (mPC)
Primary outcomes (1)
- measure
- Validation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy
- timeFrame
- 3 years
- description
- Validation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy in patients with metastatic prostate cancer (mPC) whose tumor tissue is inadequate or unavailable for molecular testing.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. Exclusion Criteria: * Unable to provide written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.